Abbott Laboratories Slides to Near 52-Week Low as Selling Pressure Persists
By TrendSpider Editor
Abbott Laboratories is trading at $90.34, just cents above its 52-week low of $90.29, after sliding another 0.32% on Friday, May 1, 2026. The stock has shed considerable ground from its 52-week high of $139.05, representing a drawdown of more than 35% over the past year. With price action hugging th
Abbott Laboratories Slides to Near 52-Week Low as Selling Pressure Persists
Abbott Laboratories is trading at $90.34, just cents above its 52-week low of $90.29, after sliding another 0.32% on Friday, May 1, 2026. The stock has shed considerable ground from its 52-week high of $139.05, representing a drawdown of more than 35% over the past year. With price action hugging the bottom of its annual range, ABT is drawing close attention from traders watching for either a technical breakdown or a potential floor.
Key Drivers of the ABT Stock Move
- Main Catalyst: ABT is a near 52-week low mover, with today's session price of $90.34 sitting just $0.05 above the 52-week floor of $90.29 set during yesterday's session. The stock printed a high of $91.48 intraday before fading, failing to hold any meaningful bounce.
- Bull Case: The proximity to the 52-week low of $90.29 may attract value-oriented and mean-reversion buyers who view a stock that has fallen from $139.05 as deeply oversold. A hold at current levels could set the stage for a technical base to form.
- Bear Case: The 52-week range of $90.29 to $139.05 illustrates just how dominant the downtrend has been. The failure to reclaim even the intraday high of $91.48 on a day the stock brushed its annual low signals persistent distribution and limited near-term buying conviction.
The forward setup for ABT is precarious from a purely technical standpoint. A close below $90.29 would constitute a fresh 52-week low and could accelerate selling from momentum-driven strategies and stop-loss triggers. The narrow gap between the current price and that critical support level leaves virtually no margin for error for bulls. Until ABT can reclaim ground meaningfully above the $91.48 intraday high seen this week and build higher lows, the path of least resistance remains to the downside. Traders will be monitoring whether end-of-week and end-of-month positioning flows, which can exaggerate price moves in either direction, played a role in today's pressure or whether this represents genuine continuation selling heading into next week.
ABT Seasonality
May has historically been a mixed month for large-cap healthcare names, with the "sell in May" seasonal narrative occasionally adding headwinds to stocks already under technical pressure. For a stock pressing against a 52-week low in early May, seasonal patterns offer little near-term relief.
ABT Relative Performance
ABT's decline of 0.32% on May 1, 2026, and its position just above a 52-week low of $90.29 suggest it is meaningfully underperforming broader healthcare sector peers and the general market. The magnitude of the drawdown from the 52-week high of $139.05 to the current price of $90.34 points to ABT lagging significantly on a trailing 12-month basis relative to diversified large-cap benchmarks, where losses of this scale are far less common among blue-chip constituents.